Trial site
Hosp Clinico Univ de Salamanca
Salamanca, 37007, SpainNot linked to an institution yet
- 6running trials
- 9closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 24 trials
- Phase 13 trials
- Status
- Completed8 trials
- Active, not recruiting3 trials
- Recruiting3 trials
- Withdrawn1 trial
- Lead sponsor
- Janssen Research & Development, LLC12 trials
- Actelion1 trial
- Janssen Pharmaceutica N.V., Belgium1 trial
- Janssen-Cilag Ltd.1 trial
Running trials
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03399799· Phase 1· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Real-world Study in Participants With Smoldering Multiple Myeloma
NCT06472778· Janssen-Cilag Ltd.· Source
Completed
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
NCT04968912· Phase 2· Janssen Research & Development, LLC· Source
Withdrawn
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
NCT04264806· Phase 2· Janssen Research & Development, LLC· Source
Completed
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT03904693· Phase 3· Actelion· Source
Completed
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT03900598· Phase 1· Janssen Research & Development, LLC· Source
Completed
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
NCT03573310· Phase 1· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
NCT03301220· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105· Phase 3· Janssen Research & Development, LLC· Source
Report an error